

ERRATUM

## Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival

J. Bart Rose, MD, MAS<sup>1</sup>, Flavio G. Rocha, MD<sup>1</sup>, Adnan Alseidi, MD<sup>1</sup>, Thomas Biehl, MD<sup>1</sup>, Ravi Moonka, MD<sup>1</sup>, John A. Ryan, MD<sup>1</sup>, Bruce Lin, MD<sup>2</sup>, Vincent Picozzi, MD<sup>2</sup>, and Scott Helton, MD<sup>1</sup>

<sup>1</sup>Section of General, Thoracic and Vascular Surgery, Department of Surgery, Virginia Mason Medical Center, Seattle, WA;

<sup>2</sup>Section of Medical Oncology, Department of Medicine, Virginia Mason Medical Center, Seattle, WA

### ERRATUM TO: ANN SURG ONCOL DOI 10.1245/S10434-014-3486-Z

An error occurred in the Methods section, which is corrected here. The first sentence in the second paragraph, under the heading “Neoadjuvant Chemotherapy Regimen,” should read:

Eligible patients were started on an eight-cycle course of 1,000 mg/m<sup>2</sup> of gemcitabine and **40** mg/m<sup>2</sup>

of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels.

The sentence as originally published, “Eligible patients were started on an eight-cycle course of 1,000 mg/m<sup>2</sup> of gemcitabine and 80 mg/m<sup>2</sup> of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels,” is incorrect.

---

The online version of the original article can be found under doi:[10.1245/s10434-014-3486-z](https://doi.org/10.1245/s10434-014-3486-z).

---

© Society of Surgical Oncology 2014

Published Online: 17 March 2014

J. B. Rose, MD, MAS  
e-mail: [bart.rose@vmmc.org](mailto:bart.rose@vmmc.org)